Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Moderna (MRNA) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

It's not a just a revolutionary and safe vaccine technology – mRNA could help make the best and most expensive drugs in the ...

JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $33 from $40 and keeps an Underweight rating on the shares, ...

The researchers identified 1248 major structural birth defects among 78,052 pregnancies: 1049 in unvaccinated people and 199 in vaccinated people (160.6 and 156.4 per 10,000 live births, respectively) ...

Rep. Marjorie Taylor Greene calls for yanking FDA approval of COVID-19 vaccines, says that "COVID-19 vaccines are causing ...

Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

From muddying the waters on vaccine policy to espousing MAHA, Kennedy’s first month in office offers a glimpse into the next four years of public health.

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

U.S. health agency leadership and policymakers seem intent on undermining trust in mRNA, the technology that saved millions of lives during the covid pandemic and has shown promise in addressing a ...